EyewireTV

04.17.2024

Watch Episode

Stocks

Sort by:

Change A-Z

AbbVie $166.06 0.85%

Adverum Biotechnologies $11.01 -1.26%

Alcon $79.40 1.19%

Aldeyra Therapeutics $3.90 -2.14%

Alimera Sciences $3.63 5.38%

Apellis Pharmaceuticals $47.23 -0.59%

Astellas Pharma $9.47 0.11%

Bausch + Lomb $14.49 1.19%

Bausch Health Companies $8.62 0.23%

Bayer $7.04 -0.21%

Biogen $191.00 0.25%

Can-Fite Biopharma $1.99 1.02%

Clearside Biomedical $1.42 7.58%

Cooper Companies $90.52 0.12%

Eyenovia $0.57 8.27%

EyePoint Pharmaceuticals $17.11 -2.26%

Glaukos $96.64 1.59%

Harrow Health $10.84 -0.09%

Hill-Rom $155.96 0.03%

Horizon Therapeutics $116.30 0.00%

InMed Pharmaceuticals $0.30 0.33%

Iridex Corporation $2.98 -1.32%

Johnson & Johnson $146.73 0.68%

Kala Pharmaceuticals $6.81 0.00%

Kiora Pharmaceuticals $0.50 -1.57%

Lensar $3.13 -0.32%

Lineage Cell Therapeutics $1.15 -4.17%

MeiraGTx Holdings $5.00 -0.20%

Merck & Company $125.40 0.14%

National Vision Holdings $18.47 -1.34%

NovaBay Pharmaceuticals $0.08 0.24%

Novartis AG Common Stock $93.91 1.45%

Ocugen $1.30 -1.89%

Ocular Therapeutix $5.24 -10.58%

Oculis $11.77 -0.08%

Ocuphire Pharma $1.68 0.60%

Omeros Corp. $3.14 -2.18%

Osmotica $1.11 -1.77%

Outlook Therapeutics $8.13 -1.93%

Palatin Technologies $1.88 -0.53%

Regeneron $892.71 -0.14%

Regenxbio $15.58 -3.29%

Roche $30.05 -0.10%

Sight Sciences $5.25 0.19%

STAAR Surgical Company $46.23 -1.15%

Takeda Pharmaceutical Company $13.20 0.30%

Tarsus Pharmaceuticals $33.16 0.94%

Viatris $11.23 0.94%

View More Stocks

Cataract

Management of Advanced Glaucoma

Nathan M. Radcliffe, MD; Blake Williamson, MD, MPH; and Gary Wörtz, MD

Eyetube

Nathan M. Radcliffe, MD, joins Blake Williamson, MD, MPH, and Gary Wörtz, MD, to share his experiences managing complex patients with advanced-stage glaucoma. He shares a specific case of an 83-year-old man with a cataract and exfoliation glaucoma with an IOP of 56 mm Hg. Dr. Radcliffe walks through how he managed complications he encountered during the combined cataract and glaucoma surgery, including vitreous prolapse and suprachoroidal hemorrhage. The surgeons also discuss how to educate and counsel patients with advanced-stage disease to help them understand realistic surgical outcomes.

Dense Cataract in Pseudoexfoliation Syndrome

Marisa Schoen, MD

Eyetube

OMDI as an Alternative to Prostaglandin Analogues in Low or Nonresponders

Joseph F. Panarelli, MD; and Neda Shamie, MD

Eyetube

Rare Case of Retrolenticular Pseudohypopyon

Sarvesswaran Prakash, MD; Aditi Ghosh, MD; and Shivkumar Chandrashekaran, MD

Eyetube

A Model for Green Cataract Surgery

Kannusamy Veena, MD; Snigdha Mishra, MD; Rengaraj Venkatesh, MD

Eyetube

Understanding Posterior Capsule Behavior

Jaime Zacharias, MD; Nicolas Berthet, MD; and Diego Orellana, MD

Eyetube

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

Eyewire News

04.12.2024

Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRS

Eyewire News

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

Eyewire News

04.08.2024

Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgery

Eyewire News

Refractive

50 Years of the ASCRS

Past and present chief medical editors of CRST reflect on the impact ASCRS has had.

Cataract and Refractive Surgery Today

“ASCRS was essentially ophthalmology’s first surgical subspecialty society. It was founded 50 years ago to fill an important but unmet need for education about a controversial new technology. Cataract surgeons needed a more progressive organization and a forum through which they could learn about IOLs, share their experiences, collaborate on research, train their colleagues, and eventually define clinical best practices. Over the next half-century, this cycle was repeated for every major advance in anterior segment surgery, including phacoemulsification, keratorefractive surgery, refractive IOLs, biometry and IOL formulas, noncapsular IOL fixation, lamellar corneal transplantation, femtosecond laser–assisted cataract surgery, and MIGS. A society devoted to anterior segment surgery brought that focus to its conferences, peer-reviewed and trade journals, online education, legislative advocacy, and philanthropy. The ASCRS Film Festival, which was the brainchild of Spencer Thornton, MD, and David Karcher, celebrated the emerging and quintessential role of video for teaching surgical techniques. Today, most major countries have their own national cataract and refractive surgery society modeled after ASCRS and, in many cases, founded with the help and initial support of ASCRS. As a result, no other single organization has had a greater impact on innovation and the dissemination of new anterior segment surgical technology and techniques worldwide. Finally, at a time when academicians controlled most of what was presented at the AAO annual meeting, ophthalmologists in private practice founded ASCRS and have played a key role in the organization ever since. I am personally grateful for the opportunities that ASCRS gave me, a private practitioner, to contribute to our profession over the course of my career.”

Essential Preoperative Considerations

Clinical examination findings and diagnostic imaging are critical to success.

Tanya Trinh, MBBS, FRANZCO, FWCRS, and Nicole Fram, MD

Cataract and Refractive Surgery Today

Treating Astigmatism With Femtosecond Laser

Omar F. Almallah, MD

Eyetube

The Strategic Expansion of Middle Segment Surgery

Training, techniques, and future directions.

Sadeer B. Hannush, MD

Cataract and Refractive Surgery Today

The Future of Hyperopic LASIK: Debates and Advances

William F. Wiley, MD, and Wesam Silk, MD

Eyetube

Management of Advanced Glaucoma

Nathan M. Radcliffe, MD; Blake Williamson, MD, MPH; and Gary Wörtz, MD

Eyetube

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

Eyewire News

04.11.2024

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgery

Eyewire News

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

Eyewire News

04.04.2024

Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)

Eyewire News

Stay Updated

Retina

The Importance of Serial OCT Scans in Tractional Retinal Detachment

Ahmed Abdelshafy, MD

Eyetube

In this video, Ahmed Abdelshafy, MD, shows the importance of serial OCT scans in cases of vitreomacular traction. In this case, Dr. Abdelshafy performs tractional retinal detachment repair in the eye of a 55-year-old patient.

Adopting Remote Monitoring and AI: Lessons From Cardiology

Learning from colleagues in other medical specialties can guide ophthalmology’s smooth transition.

Judy E. Kim, MD, FARVO, FASRS, and Jagmeet P. Singh, MD, ScM, PhD, FHRS, FACC

Retina Today

The Utility of En Face OCT for Detecting Neovascularization in DR

We conducted a study of our own to better understand this association.

Mizuki Hamada, MD, and Kotaro Tsuboi, MD

Retina Today

New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to Foveal Status and Time of Surgery

Lediana Goduni, MD; Matthew R. Starr, MD; and Joshua H. Uhr, MD

Eyetube

Severe Diabetic Retinopathy With Epiretinal Fibrous Tissue and Tractional Retinal Detachment

Hudson Nakamura, MD

Eyetube

New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT

Sruthi Arepalli, MD, Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH

Eyetube

04.18.2024

Ocular Therapeutix’ Axpaxli in Diabetic Retinopathy Evaluated in Phase 1 HELIOS Clinical Trial

Eyewire News

04.16.2024

Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovation

Eyewire News

04.15.2024

iHealthScreen Awarded US Patent on Glaucoma Detection Based on AI and Color Fundus Imaging

Eyewire News

04.15.2024

In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streaks

Eyewire News

Glaucoma

Is Glaucoma Policy Short-Sighted?

Redefining innovation to keep an eye on patient access.

Sara Riaz, MSc; Blake Oberfeld, MD; Hani El Helwe, MD; Henisk Falah, BS; and David Solá-Del Valle, MD

Glaucoma Today

Glaucoma is an incurable disease and a leading cause of blindness that is expected to affect up to 120 million people by 2040.1 In the United States, glaucoma specialists complete at least 13 years of rigorous training to manage this prevalent disease, yet reimbursement for glaucoma care is largely dictated by US health insurance payers. Last year, multiple Medicare Administrative Contractors (MACs) announced that they would no longer cover several MIGS procedures. Ultimately, lobbying by patient advocacy groups, glaucoma specialists, and ophthalmology societies, among others, led to the reversal of this controversial coverage policy.2 Nevertheless, other modern and effective glaucoma treatments such as certain standalone and combined MIGS procedures, drug delivery systems, new antiglaucoma medications, and preservative-free antiglaucoma drugs remain at risk of coverage restrictions. When insurers do not cover costs, patients must either pay out of pocket or lose access, potentially worsening inequities in eye care.3 Health care policy plays a crucial role in controlling the costs of care at a population level. However, policies guiding glaucoma care should also account for the lack of curative therapies, the limitations of feasible research, patient-specific factors directing treatment, and the burden of patient nonadherence. In this sense, we would argue that, for glaucoma policy, reimbursement rules should not be designed to discourage research and innovation and that, for ophthalmologists, innovation should not stop at the development of new drugs and devices. To balance care and costs, innovation should continue through the long-term study of cost-effectiveness and quality-of-life improvements that existing glaucoma drugs and devices can offer. With the help of industry and government, ophthalmologists should be ready to lead data-driven policy reform, ensuring that patients can access the care they need and deserve. AT A GLANCE Glaucoma policy determinations may be failing to meet the goals of patients and practitioners as well as the overall policy goal of controlling costs. The ophthalmology community and policymakers must take innovation a step further by studying the long-term cost-effectiveness of existing treatments and the impact that restrictive coverage policies can have on patient quality of life.

The Buzz on Eyetube

Glaucoma Today

Hydrus Microstent Removal and Repositioning

I. Paul Singh, MD

Eyetube

iTrack Canaloplasty With 90° Goniotomy

I. Paul Singh, MD

Eyetube

Genetics: Now or Later?

Why it’s time to know the basics.

Inas F. Aboobakar, MD

Glaucoma Today

Triple Threat: Combination OMNI and Hyrdus

Roman Krivochenitser, MD

Eyetube

04.15.2024

iHealthScreen Awarded US Patent on Glaucoma Detection Based on AI and Color Fundus Imaging

Eyewire News

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

Eyewire News

04.11.2024

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNI

Eyewire News

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

Eyewire News

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Pupil Pod

A case-based podcast hosted by Sila Bal, MD, MPH, featuring all stages of the journey through ophthalmology, from first-year residents to the leading experts.

View Feed

Optometry

Autoimmune Disease and the Eye

Many affected patients will present with ocular signs and symptoms.

Anthony DeWilde, OD, FAAO

Modern Optometry

Autoimmune diseases are a complex set of conditions, in which the immune system mistakenly targets healthy cells instead of foreign cells. This can lead to significant morbidity and mortality. Autoimmune disease is the second highest cause of chronic illness in the United States. All in all, there are more than 80 types of autoimmune diseases.1 Diagnosing autoimmune diseases can be difficult, often due to lack of access to health care, testing options that are expensive and difficult to obtain, lack of specificity with testing modalities, and vague symptoms. From initial symptoms to final diagnosis, the process typically takes an average of 4.5 years and involves up to four doctors.2 ODs are in a unique position to help patients with autoimmune disease, as many of these conditions manifest with ocular signs and symptoms. By understanding the association between autoimmune disease and the eye, we can detect early signs and symptoms, allowing earlier referral and treatment. The number of autoimmune diseases that can affect the eye is vast. As such, this article will focus on the three main conditions that I’ve encountered over the course of my career: myasthenia gravis (MG), thyroid eye disease (TED), and giant cell arteritis (GCA). MYASTHENIA GRAVIS MG is a chronic autoimmune disease where autoantibodies bind to the neuromuscular junction, blocking its ability to receive normal signals from acetylcholine. This manifests as muscle weakness and fatigue.

A Place for House Calls in Optometry

Consider delivering eye care where it’s needed most.

Damaris Raymondi, OD, FAAO

Modern Optometry

Successful Management of Vitreous Opacities

Eyetube

The Promise of Drug-Eluting Contact Lenses

The future looks bright for this technology.

Alex Hynes, OD, FAAO

Modern Optometry

In Consideration of House Calls and OD-to-OD Referrals

Eyetube

The State of Optometry’s Financial Health

Five takeaways from the largest income survey conducted in optometry.

Aaron Neufeld, OD

Modern Optometry

04.10.2024

Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the World

Eyewire News

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

Eyewire News

04.05.2024

Wearing Glasses Boosts Income by a Third in Low-Income Communities, Finds Landmark New Study

Eyewire News

04.04.2024

Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)

Eyewire News

Business

How Digital Health Helps Differentiate Your Optometric Practice

Understand what digital health is and learn how it can distinguish your clinic now and in the future.

Timothy Earley, OD

Modern Optometry

Some optometrists struggle to differentiate their practices from those of their colleagues, and some patients assume that all optometric practices are similar. These patients don’t realize that so many of us have special interests in different areas, such as managing the effects of age-related macular degeneration (AMD), comanaging patients with glaucoma, or treating ocular surface disease. Those of us in medically oriented optometry must therefore distinguish ourselves from nonspecialty eye care. But major capital investments can be daunting, and even if investments were an option, it may be difficult to discern which routes will yield the highest return. This is where expansion of digital health presents a solution to optometrists, as doctors can differentiate their clinic, increase the quality of care offered to patients, avoid steep start-up costs, and create new revenue streams. Before we dive into which specific platforms may be useful to clinicians seeking to expand their digital health offerings, we will first review what digital health is and why it may be attractive to those seeking to grow their clinic’s reach. WHAT IS DIGITAL HEALTH? Digital health is not the mere use of digital tools in a clinical setting. Rather, it is a framework for conceptualizing and executing a practice plan that leverages emerging technologies to provide patients with convenient, high-quality care, thereby empowering a clinician to deliver care irrespective of their physical proximity to the patient. In short, properly implemented digital health increases the quality of patient care without requiring more clinician hours.

Expand Your Opportunities for Profitability

Consider adding these technologies to your practice and reap the rewards.

Christopher Lopez, OD

Modern Optometry

Why You Should Hire an Associate OD

Welcoming another eye care practitioner to your practice can accelerate practice growth and expand your range of services offered.

Christopher Lopez, OD

Modern Optometry

Tips for Retaining Staff and Keeping Them Happy

A solid team is at the core of any successful practice. Here’s how you can do your part as a leader to ensure employee satisfaction.

Michael J. Cymbor, OD, FAAO; Mila Ioussifova, OD, FAAO, CNS; and Caitlin Morrison, OD, FAAO, FSLS

Modern Optometry

Shielding Your Wealth From Potential Liability

The basics of a solid asset protection plan.

David B. Mandell, JD, MBA

Modern Optometry

Determining When to Use Modifiers -58 and -78

Both are used in association with the original surgery, but ultimately serve different purposes.

Joy Woodke, COE, OCS, OCSR

Retina Today

04.16.2024

Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovation

Eyewire News

04.16.2024

EyeSouth Partners Affiliates With Community Eye Care Specialists in New York

Eyewire News

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

Eyewire News

04.12.2024

False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reporting

Eyewire News

EyewireTV

04.17.2024

04.17.2024

Executive Updates

Bausch + Lomb

Alcon

AbbVie

Tarsus Pharmaceuticals

Centricity Vision

Sydnexis

Azura Ophthalmics

iOR Partners

Eyewire News

Ocular Therapeutix’ Axpaxli in Diabetic Retinopathy Evaluated in Phase 1 HELIOS Clinical Trial

Aqueous Humor Proteome Database Established by Medical College of Georgia

Schwind Names Lohith Shetty Head of Global Marketing

Stocks

Cataract

Management of Advanced Glaucoma

Dense Cataract in Pseudoexfoliation Syndrome

OMDI as an Alternative to Prostaglandin Analogues in Low or Nonresponders

Rare Case of Retrolenticular Pseudohypopyon

A Model for Green Cataract Surgery

Understanding Posterior Capsule Behavior

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

04.12.2024

Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRS

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

04.08.2024

Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgery

Refractive

50 Years of the ASCRS

Essential Preoperative Considerations

Treating Astigmatism With Femtosecond Laser

The Strategic Expansion of Middle Segment Surgery

The Future of Hyperopic LASIK: Debates and Advances

Management of Advanced Glaucoma

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

04.11.2024

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgery

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

04.04.2024

Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)

Stay Updated

Follow Eyewire News

Retina

The Importance of Serial OCT Scans in Tractional Retinal Detachment

Adopting Remote Monitoring and AI: Lessons From Cardiology

The Utility of En Face OCT for Detecting Neovascularization in DR

New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to Foveal Status and Time of Surgery

Severe Diabetic Retinopathy With Epiretinal Fibrous Tissue and Tractional Retinal Detachment

New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT

04.18.2024

Ocular Therapeutix’ Axpaxli in Diabetic Retinopathy Evaluated in Phase 1 HELIOS Clinical Trial

04.16.2024

Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovation

04.15.2024

iHealthScreen Awarded US Patent on Glaucoma Detection Based on AI and Color Fundus Imaging

04.15.2024

In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streaks

Glaucoma

Is Glaucoma Policy Short-Sighted?

The Buzz on Eyetube

Hydrus Microstent Removal and Repositioning

iTrack Canaloplasty With 90° Goniotomy

Genetics: Now or Later?

Triple Threat: Combination OMNI and Hyrdus

04.15.2024

iHealthScreen Awarded US Patent on Glaucoma Detection Based on AI and Color Fundus Imaging

04.15.2024

Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEO

04.11.2024

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNI

04.09.2024

Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plug

Featured Podcasts